Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
Holubar et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac312 (preprint 11/24/2021)
https://c19early.org/holubar.html